Product Description & Mechanism of Action
Riomox CV 625 is a premier broad-spectrum antibiotic formulation combining Amoxicillin Trihydrate with Potassium Clavulanate. The addition of Clavulanic Acid inactivates beta-lactamase enzymes produced by resistant bacteria, thereby extending Amoxicillin’s spectrum of activity to include organisms normally resistant to beta-lactam antibiotics.
Pharmacological Mechanism:
Amoxicillin acts by inhibiting bacterial cell wall peptidoglycan synthesis during active multiplication, causing osmotic lysis and cell death. Potassium Clavulanate is a suicide inhibitor of beta-lactamase enzymes, preventing the enzymatic degradation of Amoxicillin.
Dosage & Administration Guidelines
Recommended Administration:
Adults and adolescents (>40 kg): One tablet of Riomox CV 625 twice daily (every 12 hours) after meals, or as prescribed by a registered medical practitioner. Course duration typically ranges from 5 to 14 days.
Precautions & Safety:
Contraindicated in patients with a history of severe hypersensitivity (anaphylaxis) to penicillin or cephalosporin antibiotics, or a history of amoxicillin/clavulanate-associated hepatic dysfunction.